These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15593048)

  • 21. [mTOR signal pathway and its inhibitors in antitumor therapy: a review].
    Huang JJ; Lin TY
    Ai Zheng; 2007 Dec; 26(12):1397-403. PubMed ID: 18076811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. mTOR inhibitors and calcineurin inhibitors do not affect adhesion molecule expression of human macro- and microvascular endothelial cells.
    Lehle K; Schreml S; Kunz-Schughart LA; Rupprecht L; Birnbaum DE; Schmid C; Preuner JG
    J Vasc Res; 2008; 45(4):333-42. PubMed ID: 18319592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients.
    Tenderich G; Fuchs U; Zittermann A; Muckelbauer R; Berthold HK; Koerfer R
    Clin Transplant; 2007; 21(4):536-43. PubMed ID: 17645716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [3/3 Inhibitors of mTOR (sirolimus and everolimus)].
    Chaumard N; Limat S; Woronoff-Lemsi MC
    Soins; 2007 Sep; (718):63-4. PubMed ID: 17970580
    [No Abstract]   [Full Text] [Related]  

  • 25. Sirolimus: its role in nephrology.
    Lee VW; Chapman JR
    Nephrology (Carlton); 2005 Dec; 10(6):606-14. PubMed ID: 16354246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
    Figlin RA
    Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991-2005.
    Chang SH; Russ GR; Chadban SJ; Campbell S; McDonald SP
    Nephrology (Carlton); 2008 Apr; 13(2):171-6. PubMed ID: 18275507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Everolimus in clinical practice--renal transplantation.
    Pascual J
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sirolimus in renal transplantation.
    Morath C; Arns W; Schwenger V; Mehrabi A; Fonouni H; Schmidt J; Zeier M
    Nephrol Dial Transplant; 2007 Sep; 22 Suppl 8():viii61-viii65. PubMed ID: 17890266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. mTOR inhibitors and their secondary effects in cardiac transplant recipients: a descriptive study.
    Moro J; Almenar L; Martínez-Dolz L; Izquierdo M; Rueda J; Arnau MA; Agüero J; Sánchez-Lázaro I; Ortiz V; Salvador A
    Transplant Proc; 2007 Sep; 39(7):2365-7. PubMed ID: 17889191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors.
    Eisen H; Kobashigawa J; Starling RC; Valantine H; Mancini D
    Transplant Proc; 2005 May; 37(4 Suppl):4S-17S. PubMed ID: 15809102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Everolimus and mTOR inhibitors in liver transplantation: opening the "box".
    Everson GT
    Liver Transpl; 2006 Nov; 12(11):1571-3. PubMed ID: 17058246
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna.
    Zuckermann A
    J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S206-9; discussion S210-1. PubMed ID: 15774324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pros and the cons of mTOR inhibitors in kidney transplantation.
    Ponticelli C
    Expert Rev Clin Immunol; 2014 Feb; 10(2):295-305. PubMed ID: 24377908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation.
    Zuckermann A; Manito N; Epailly E; Fiane A; Bara C; Delgado JF; Lehmkuhl H; Ross H; Eisen H; Chapman J; Valantine H
    J Heart Lung Transplant; 2008 Feb; 27(2):141-9. PubMed ID: 18267219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat.
    Vogelbacher R; Wittmann S; Braun A; Daniel C; Hugo C
    Transplantation; 2007 Dec; 84(11):1492-9. PubMed ID: 18091526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.
    Gaumann A; Schlitt HJ; Geissler EK
    Transpl Int; 2008 Mar; 21(3):207-17. PubMed ID: 18069922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapamycin: an anti-cancer immunosuppressant?
    Law BK
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):47-60. PubMed ID: 16039868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.
    Amato RJ; Jac J; Giessinger S; Saxena S; Willis JP
    Cancer; 2009 Jun; 115(11):2438-46. PubMed ID: 19306412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
    Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
    Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.